Retrospective Study of Patients With Type 2 Diabetes Mellitus on Dapagliflozin Therapy in Taiwan

Inclusion Criteria

• 1. Outpatient equal to or more than 20 years of age.
• 2. T2DM patient initiated dapagliflozin after May 1st 2016 as a second line
• or third line oral anti-diabetic therapy, either as add-on or switching from one to another. Or initiating dapagliflozin as adjunctive therapy for T2DM subjects treated with insulin.
• 3. Completed follow-up of at least 6 months regardless of continuation on dapagliflozin therapy.
• 4. Will provide completed and signed written informed consents.